SCHEMBL4353258

SCHEMBL4353258

CC[Si](CC)(CC)C(C(N)=O)[Si](CC)(CC)CC

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
ALOX15 P16050 2/20 0.32
EPHX1 P07099 1/20 0.30
LMNA P02545 1/20 0.30
BLM P54132 1/20 0.30
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5435336 0.78 CA1 (0.34) CA1CA2ALOX15EPHX1LMNA
SCHEMBL9022618 0.75 CA2 (0.43) CA1CA2ALOX15EPHX1
SCHEMBL11373046 0.72
SCHEMBL31396679 0.70 CA1 (0.39) CA1CA2EPHX1
SCHEMBL28309381 0.69 CA1 (0.33) CA1CA2EPHX1
SCHEMBL222605 0.67 LMNA (0.35) ALOX15LMNABLMPMP22
SCHEMBL9328869 0.67 ALDH1A1 (0.33)
SCHEMBL3586576 0.65 LMNA (0.33) ALOX15LMNABLMPMP22
SCHEMBL7890644 0.61 FDPS (0.39) CA1CA2ALOX15EPHX1LMNA
SCHEMBL8312889 0.61 LMNA (0.30) ALOX15LMNABLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2808329-B1 Silyl-Protected Nitrogen-Containing Cyclic Compounds and their method of preparation SHINETSU CHEMICAL CO (JP) 2018-09-26 EP disclosed
US-9745386-B2 Anti-chondroitin-sulfate-E antibody SEIKAGAKU CORPORATION (JP) 2017-08-29 US disclosed
US-20170107301-A1 ANTI-CHONDROITIN-SULFATE-E ANTIBODY SEIKAGAKU CORPORATION (JP) 2017-04-20 US disclosed
EP-3127922-A1 ANTI-CHONDROITIN-SULFATE-E ANTIBODY Seikagaku Corporation (JP) 2017-02-08 EP disclosed
US-9233988-B2 Silyl-protected nitrogen-containing cyclic compounds and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-01-12 US disclosed
EP-2895546-A1 IMPROVED BONDING COMPOSITION COMPRISING A SULFUR IMPREGNATED PARTICULATE SOLID Henkel IP & Holding GmbH (DE) 2015-07-22 EP disclosed
EP-2895544-A1 IMPROVED BONDING COMPOSITIONS Henkel IP & Holding GmbH (DE) 2015-07-22 EP disclosed
US-20140357862-A1 SILYL-PROTECTED NITROGEN-CONTAINING CYCLIC COMPOUNDS AND MAKING METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-12-04 US disclosed
EP-2808329-A1 Silyl-Protected Nitrogen-Containing Cyclic Compounds and Making Method Shin-Etsu Chemical Co., Ltd. (JP) 2014-12-03 EP disclosed
WO-2014040645-A1 IMPROVED BONDING COMPOSITION COMPRISING A SULFUR IMPREGNATED PARTICULATE SOLID HENKEL AG & CO. KGAA (DE) 2014-03-20 WO disclosed
EP-0484094-B1 Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use SANKYO CO (JP) 1996-06-26 EP disclosed
EP-0323427-A2 Light-sensitive compositions with phenol resins and quinone diarides U C B, S.A. (BE) 1989-07-05 EP disclosed
EP-0248779-A1 Process for producing positive patterns in a photoresist layer U C B, S.A. (BE) 1987-12-09 EP disclosed
EP-0033965-B1 NEW CEPHEM COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1985-05-15 EP disclosed
US-4460502-A Peptide, process for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-07-17 US disclosed
US-4385176-A RING EXPANSION USING A LEWIS ACID FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1983-05-24 US disclosed
EP-0051812-A1 Peptide, process for preparation thereof and use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-05-19 EP disclosed
US-4308380-A 2-Lower alkyl-2 or 3-cephem-4-carboxylic acid derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-12-29 US disclosed
US-4113940-A ANTIMICROBIAL FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1978-09-12 US disclosed
US-4105648-A CROSSLINKED POLYACRYLAMIDES CONTAINING SILYL GROUPS CIBA-GEIGY CORPORATION (US) 1978-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357862-A1 SILYL-PROTECTED NITROGEN-CONTAINING CYCLIC COMPOUNDS AND MAKING METHOD PRMT9, CCNO, IPO9 CA1 668/4885CA2 2436/4885ALOX15 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.